Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma.

@article{Ozawa2009RestorationOB,
  title={Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma.},
  author={Shigeyuki Ozawa and Yasumasa Kato and Shin Ito and Reika Komori and Naoto Shiiki and Keiichi Tsukinoki and Satoru Ozono and Yojiro Maehata and Takahide Taguchi and Yukari Imagawa-Ishiguro and Mamoru Tsukuda and Eiro Kubota and Ryu-ichiro Hata},
  journal={Cancer science},
  year={2009},
  volume={100 11},
  pages={
          2202-9
        }
}
Clinical efficacy of gefitinib (ZD1839, Iressa), which is an inhibitor specific for epidermal growth factor (EGF) receptor tyrosine kinase, has been shown in non-small-cell lung carcinoma patients with EGF receptor mutations, so these mutations are useful marker(s) to find a responder for the drug. Recent studies have shown that the EGF receptor gene mutation is rare in squamous cell carcinoma in the esophageal and head and neck regions. We previously reported that the expression of the… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

C-X-C Motif Chemokine Ligand 14 is a Unique Multifunctional Regulator of Tumor Progression

  • International journal of molecular sciences
  • 2019
VIEW 5 EXCERPTS
CITES BACKGROUND

Identification of liver metastasis-associated genes in human colon carcinoma by mRNA profiling

  • Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
  • 2018